相似文献
1
Conventional trial designs offer limited clinical understanding of cholinesterase-inhibitor treatment effects in Alzheimer disease.
Am J Geriatr Psychiatry. 2005 Feb;13(2):170; author reply 170-1. doi: 10.1176/appi.ajgp.13.2.170.
2
Ethical issues in placebo-controlled trials in Alzheimer disease.
Med J Aust. 2001 Jan 15;174(2):104-5. doi: 10.5694/j.1326-5377.2001.tb143168.x.
3
Metrifonate for Alzheimer's disease: is the next cholinesterase inhibitor better?
Neurology. 1998 May;50(5):1203-5. doi: 10.1212/wnl.50.5.1203.
4
[Acetylcholinesterase inhibitor. Helpful not just in Alzheimer dementia].
MMW Fortschr Med. 2002 Aug 22;144(33-34):59.
5
[Alzheimer patients treated with anti-dementia drugs despite unanswered questions].
Fortschr Med Orig. 2001 Nov 29;119(3-4):141-3.
6
Rivastigmine for Alzheimer's disease.
Drug Ther Bull. 2000 Feb;38(2):15-6.
7
Donepezil for Alzheimer's disease?
Drug Ther Bull. 1997 Oct;35(10):75-6.
8
Alzheimer's disease: the role of tacrine therapy.
Iowa Med. 1995 Oct;85(10):409-11.
9
Donepezil for Alzheimer's disease.
J Fam Pract. 1998 May;46(5):356.
10
Metrifonate: overview of safety and efficacy.
Pharmacotherapy. 1998 Mar-Apr;18(2 Pt 2):43-6; discussion 79-82.
引用本文的文献
1
Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics.
Drugs Aging. 2005;22 Suppl 1:1-26. doi: 10.2165/00002512-200522001-00002.
Zotero 插件